



(51) International Patent Classification:

C12N 15/09 (2006.01) C12Q 1/68 (2018.01)
C12N 15/11 (2006.01) C12Q 1/6883 (2018.01)
C12N 15/113 (2006.01) C12Q 1/6886 (2018.01)

(21) International Application Number:

PCT/US2021/029361

(22) International Filing Date:

27 April 2021 (27.04.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/017,552 29 April 2020 (29.04.2020) US
63/024,875 14 May 2020 (14.05.2020) US

(71) Applicant: **FREENOME HOLDINGS, INC.** [US/US];
279 East Grand Avenue, 5th Floor, South San Francisco,
California 94080 (US).

(72) Inventors: **ARMSTRONG, Frances**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US). **MAHAJAN, Shivani**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US). **HARVEY, Adam**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US). **TEWARI, Ance-sha**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US). **WEINBERG, David**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US). **EATON, Jesse**; 279 East Grand Avenue, 5th Floor, South San Francisco, California 94080 (US).

(74) Agent: **WONG, Dawson**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

(54) Title: RNA MARKERS AND METHODS FOR IDENTIFYING COLON CELL PROLIFERATIVE DISORDERS




FIG. 2

(57) Abstract: The present disclosure pertains to miRNAs that are differentially expressed in samples of an individual having colon cell proliferative disorder, or having a high risk of developing colon cell proliferative disorder, as compared to the corresponding sample of an individual not having colon cell proliferative disorder, or having low risk of developing colon cell proliferative disorder, respectively. In some embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a colorectal lesion and having a high risk of developing colon cell proliferative disorder as compared to the corresponding tissue sample or blood sample of an individual having the colorectal lesion and having no risk or low risk of developing colon cell proliferative disorder. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of a colon cell proliferative disorder, particularly, in a subject having a colorectal lesion.

[Continued on next page]

HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:

09 December 2021 (09.12.2021)